Seaport Therapeutics, Inc. (SPTX)

Pharmaceutical Preparations · market cap $1.1B · as of 2026-07-20

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-02 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Seaport Therapeutics (SPTX) is a clinical-stage biotech with 58 employees and a market cap of ~$973M, focused on central nervous system disorders. Its lead and only disclosed asset is SPT-300, currently in Phase 2 development for Major Depressive Disorder (MDD), with a mechanism of action not specified in available filings. The key upcoming catalyst is estimated Phase 2 data readout around March 15, 2027.

The catalyst path

2026-11-02 (est.)Earningsimp 5/10
2027-03-15 (est.)Phase 2 · SPT-300imp 7/10

Pipeline

Asset	Phase	Indication
SPT-300	Phase 2	Major Depressive Disorder (MDD)

Price & technical context

3-month

-6.0%

6-month

—

12-month

—

52-wk range

$15.25–$27.84

vs 50-day MA

-11.2%

vs 200-day MA

—

Realized vol

76.3%

Max drawdown

-32.9%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for SPTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.